LEGN: Legend Biotech Corporation Stocks News on April 2, 2025

Legend Biotech Full Year 2024 Earnings: Beats Expectations

LEGN

Simply Wall St.

21 days ago

Legend Biotech Full Year 2024 Earnings: Beats Expectations

LEGN

GuruFocus.com

21 days ago

Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Highlights: Record CARVYKTI Sales and ...

LEGN

Thomson Reuters StreetEvents

21 days ago

Q4 2024 Legend Biotech Corp Earnings Call

LEGN

Zacks

21 days ago

Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics

LEGN

MT Newswires

22 days ago

Legend Biotech's Q4 Net Loss Narrows, Revenue Rises

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

LEGN

GlobeNewswire

22 days ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

LEGN

GlobeNewswire

a month ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

LEGN

Insider Monkey

a month ago

Why Legend Biotech Corporation (LEGN) is the Most Oversold Pharma Stock to Buy According to Analysts

LEGN

Insider Monkey

a month ago

Market Concerns Put Pressure on Legend Biotech Corporation (LEGN) Shares

LEGN

Insider Monkey

a month ago

Legend Biotech Corporation (LEGN): One of the Most Oversold Healthcare Stocks to Buy Now

High Growth Tech Stocks To Watch In February 2025

LEGN

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In February 2025

LEGN

Insider Monkey

2 months ago

Is Legend Biotech (LEGN) the Best Mid-Cap Growth Stock to Buy According to Analysts?

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

LEGN

Zacks

2 months ago

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

LEGN

Insider Monkey

2 months ago

Why Legend Biotech Corporation (LEGN) Is Among the Best Healthcare Stocks To Buy According to Analysts

LEGN

Insider Monkey

2 months ago

Here’s Why Legend Biotech Corporation (LEGN) Will Double in 2025

Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?

LEGN

Zacks

2 months ago

Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?

High Growth Tech Stocks to Watch in January 2025

LEGN

Simply Wall St.

2 months ago

High Growth Tech Stocks to Watch in January 2025

LEGN

Insider Monkey

2 months ago

Legend Biotech Corporation (LEGN): The Biotech Stock with Biggest Upside Potential

LEGN

MT Newswires

3 months ago

RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating

LEGN

MT Newswires

3 months ago

Karyopharm Therapeutics Names Lori Macomber CFO

LEGN

MT Newswires

3 months ago

Top Midday Decliners

LEGN

MT Newswires

3 months ago

Legend Biotech CFO Lori Macomber to Resign, Jessie Yeung Named Interim CFO

Exploring 3 High Growth Tech Stocks In The United States

LEGN

Simply Wall St.

3 months ago

Exploring 3 High Growth Tech Stocks In The United States

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LEGN

GlobeNewswire

3 months ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success

LEGN

TipRanks

4 months ago

Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success

LEGN

MT Newswires

4 months ago

Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

LEGN

GlobeNewswire

4 months ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

LEGN

Investor's Business Daily

4 months ago

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

LEGN

MT Newswires

4 months ago

UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating

LEGN

Insider Monkey

4 months ago

Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?

LEGN

Insider Monkey

4 months ago

Legend Biotech Corp. (LEGN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

LEGN

Insider Monkey

4 months ago

Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024?

High Growth Tech Stocks in the United States to Watch

LEGN

Simply Wall St.

4 months ago

High Growth Tech Stocks in the United States to Watch

LEGN

Simply Wall St.

5 months ago

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Legend Biotech Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LEGN

Simply Wall St.

5 months ago

Legend Biotech Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

LEGN

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Legend Biotech Corp Earnings Call

LEGN

GuruFocus.com

5 months ago

Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Highlights: CARVYKTI's Impressive Growth Amid ...

LEGN

Zacks

5 months ago

Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say

LEGN

MT Newswires

5 months ago

Legend Biotech Q3 Loss Widens, Revenue Rises

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

LEGN

GlobeNewswire

5 months ago

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

LEGN

Zacks

5 months ago

Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

LEGN

GuruFocus.com

5 months ago

Legend Biotech Corp (LEGN) Q3 2024 Earnings Report Preview: What to Look For

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

LEGN

GlobeNewswire

5 months ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

LEGN

GlobeNewswire

5 months ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

LEGN

GlobeNewswire

5 months ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

LEGN

Zacks

5 months ago

Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

LEGN

GlobeNewswire

5 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

LEGN

Insider Monkey

6 months ago

Is Legend Biotech Corporation (LEGN) the Most Promising Biotech Stock According to Hedge Funds?

LEGN

MT Newswires

6 months ago

Redburn Initiates Legend Biotech at Buy With $86 Price Target

LEGN

MT Newswires

6 months ago

Legend Biotech to Open New Cell Therapy R&D Facility in Philadelphia

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

LEGN

GlobeNewswire

6 months ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

High Growth Tech Stocks To Watch In October 2024

LEGN

Simply Wall St.

6 months ago

High Growth Tech Stocks To Watch In October 2024

Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

LEGN

Investor's Business Daily

6 months ago

Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

Legend Biotech Rises After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

LEGN

Investor's Business Daily

6 months ago

Legend Biotech Rises After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

LEGN

GlobeNewswire

6 months ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma

LEGN

Investor's Business Daily

6 months ago

Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma

LEGN

Insider Monkey

7 months ago

Legend Biotech Corporation (LEGN): Among Hedge Funds’ Top Biotech Stock Picks

LEGN

Insider Monkey

7 months ago

Here’s Why TimesSquare Capital Management U.S. Focus Growth Strategy Removed Legend Biotech Corporation (LEGN) from its Portfolio

Matthews Emerging Markets Small Companies Fund Boosts Stake in Legend Biotech Corp

LEGN

GuruFocus.com

7 months ago

Matthews Emerging Markets Small Companies Fund Boosts Stake in Legend Biotech Corp

LEGN

Simply Wall St.

7 months ago

Exploring 3 High Growth Tech Stocks In The United States

LEGN

MT Newswires

7 months ago

Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

LEGN

GlobeNewswire

7 months ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

LEGN

Simply Wall St.

8 months ago

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Second-Quarter Results

LEGN

MT Newswires

8 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday

LEGN

MT Newswires

8 months ago

Legend Biotech's Q2 Loss Narrows, Revenue Climbs

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

LEGN

GlobeNewswire

8 months ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

LEGN

GlobeNewswire

8 months ago

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

LEGN

Insider Monkey

8 months ago

Is Legend Biotech Corporation (LEGN) a Good Growth Stock to Buy?

LEGN

MT Newswires

8 months ago

Legend Biotech Reports Preliminary First-Half Financial Results

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

LEGN

GlobeNewswire

8 months ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

LEGN

MT Newswires

9 months ago

TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating

LEGN

Zacks

9 months ago

Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid

LEGN

Zacks

9 months ago

Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

LEGN

GlobeNewswire

9 months ago

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

LEGN

MT Newswires

9 months ago

Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

LEGN

GlobeNewswire

9 months ago

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

LEGN

Insider Monkey

9 months ago

Does Legend Biotech (LEGN) Have a Long Runway for Growth?

LEGN

MT Newswires

10 months ago

Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target

LEGN

MT Newswires

10 months ago

Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

LEGN

Business Wire

10 months ago

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

LEGN

Business Wire

10 months ago

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

LEGN

MT Newswires

10 months ago

HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating

LEGN

MT Newswires

10 months ago

Deutsche Bank Starts Legend Biotech With Buy Rating

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

LEGN

Business Wire

10 months ago

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

LEGN

MT Newswires

10 months ago

MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program

LEGN

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating

LEGN

MT Newswires

a year ago

RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating

LEGN

GuruFocus.com

a year ago

Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...

LEGN

Thomson Reuters StreetEvents

a year ago

Q1 2024 Legend Biotech Corp Earnings Call

LEGN

MT Newswires

a year ago

Sector Update: Health Care Stocks Decline Pre-Bell Monday

LEGN

MT Newswires

a year ago

Sector Update: Health Care

LEGN

MT Newswires

a year ago

Legend Biotech Q1 Net Loss Narrows as Revenue Rises; Shares Rise Pre-Bell

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

LEGN

Business Wire

a year ago

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

LEGN

Zacks

a year ago

Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

LEGN

MT Newswires

a year ago

Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer

$CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma$